RayKnowChina Research Map
Shortlist0

Cancer

Hepatocellular carcinoma in Guangzhou

广州 肝细胞癌

All diseases in Guangzhou

14 hospitals in Guangzhou

Order: papers led on hepatocellular carcinoma, 2021–2025, then A–Z. Research activity, not a rating of care.

Only hospitals listed for hepatocellular carcinoma: those with enough papers or registered trials on it in the records this site uses. Other hospitals in Guangzhou may also treat it. “Papers led” counts English-language PubMed papers whose first or last author lists the hospital first.

  1. 281 papers led
  2. 219 papers led
  3. 171 papers led
  4. 127 papers led
  5. 66 papers led
  6. 54 papers led
  7. 54 papers led
  8. 45 papers led
  9. 39 papers led
  10. 32 papers led
    No open trial led
  11. 31 papers led
    No open trial led
  12. 25 papers led
    No open trial led
  13. 16 papers led
    No open trial led
  14. 0 papers led
    No open trial led

Hepatocellular carcinoma in every city Guangzhou on the disease page, with the national map

90

open trials on hepatocellular carcinoma with a hospital in Guangzhou

Recruiting, not yet recruiting, or by invitation, as registered on ClinicalTrials.gov on 8 Nov 2026, with a listed hospital in Guangzhou as lead sponsor or study site. 69 of them are led by a hospital in Guangzhou. Check the registry for the current status. Whether someone can take part is decided by the study team.

Only trials registered on ClinicalTrials.gov are counted. Trials registered only in China’s own registry (ChiCTR) are not.

  1. Recruiting
    A Two-Arm, Multicenter, Non-Randomized Controlled Study on the Efficacy of Yttrium-90 (Selective Internal Radiation Therapy) Therapy and Hepatic Arterial Infusion Chemotherapy (Hepatic Artery Infusion Chemotherapy) for Potentially Resectable Intermediate and Advanced Hepatocellular Carcinoma
    Phase
    N/A
    Started
    2026-08
    Registry
    NCT07070076

    Age 18 years to 75 years (registered criteria)

    Led by First Affiliated Hospital of Jinan UniversityGuangzhou

  2. Recruiting
    Sintilimab Plus Bevacizumab Biosimilar as Neoadjuvant Therapy for Resectable Hepatocellular Carcinoma
    Phase
    Phase 2
    Started
    2026-01
    Registry
    NCT07324824

    Age 18 years to Not stated (registered criteria)

    Led by Sun Yat-sen University Cancer CenterGuangzhou

  3. Recruiting
    SBRT Versus Surgical Resection for Small HCC
    Phase
    Phase 3
    Started
    2026-03
    Registry
    NCT07381660

    Age 18 years to 75 years (registered criteria)

    Led by Sun Yat-sen University Cancer CenterGuangzhou

  4. Recruiting
    TACE or Ablation Combined With Sintilimab and Ipilimumab N01 as Neoadjuvant Therapy for Resectable Hepatocellular Carcinoma With Intermediate-High Recurrence Risk
    Phase
    Phase 2
    Started
    2026-03
    Registry
    NCT07487662

    Age 18 years to 75 years (registered criteria)

    Led by First Affiliated Hospital of Sun Yat-sen UniversityGuangzhou

  5. Recruiting
    An Open-Label, Phase I Clinical Trial of Super CAR-T With GPC3-Positive Advanced Hepatocellular Carcinoma
    Phase
    Phase 1
    Started
    2026-03
    Registry
    NCT07493044

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteGuangzhou

  6. Recruiting
    Efficacy and Safety Comparison Between Intensified Therapy and Conversion Therapy For Advanced HCC After Failure of First-line
    Phase
    Phase 2
    Started
    2026-01
    Registry
    NCT07501351

    Age 18 years to 75 years (registered criteria)

    Led by Sun Yat-sen University Cancer CenterGuangzhou

  7. Recruiting
    A Phase Ib/II Trial to Evaluate the Efficacy and Safety of HH-009 for the Treatment of FGF19-positive Advanced or Unresectable HCC
    Phase
    Phase 1/Phase 2
    Started
    2026-05
    Registry
    NCT07547553

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 15 listed hospitals as study sitesBeijing, Bengbu, Changchun, Fuzhou, Guangzhou, Harbin, Hefei, Nanchang, Nanjing, Nanning, Shanghai, Shenyang, Tianjin

  8. Recruiting
    A Study of VRT106, Combined With Camrelizumab, and Apatinib for Advanced HCC
    Phase
    Phase 2/Phase 3
    Started
    2026-05
    Registry
    NCT07589244

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteGuangzhou

  9. Recruiting
    HAIC vs. TACE Combined With Sintilimab and Bevacizumab for Intermediate HCC (Beyond Up-To-Seven)
    Phase
    Phase 3
    Started
    2026-05
    Registry
    NCT07594340

    Age 18 years to Not stated (registered criteria)

    Led by Sun Yat-sen University Cancer CenterGuangzhou

  10. Recruiting
    TACE and/or HAIC Combined With Molecular-targeted Therapy and Immunotherapy for HCC
    Phase
    Not given
    Started
    2026-07
    Registry
    NCT07658833

    Age 18 years to 75 years (registered criteria)

    Led by Sun Yat-sen Memorial HospitalGuangzhou

  11. Recruiting
    HAI or IV of Adebrelimab, Combined With Bevacizumab and HAI of FOLFOX for Advanced Unresectable Hepatocellular Carcinoma
    Phase
    Phase 2
    Started
    2025-01
    Registry
    NCT06737913

    Age 18 years to Not stated (registered criteria)

    Led by Sun Yat-sen University Cancer Center; 1 listed hospital as study siteGuangzhou, Zhengzhou

  12. Recruiting
    A Study to Assess Adverse Events and Change in Disease Activity of Intravenously (IV) Infused ABBV-324 in Adult Participants With Hepatocellular Cancer (HCC) or Squamous-Cell Non-Small Cell Lung Cancer (LUSC)
    Phase
    Phase 1
    Started
    2025-04
    Registry
    NCT06858813

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesGuangzhou, Shanghai

  13. Recruiting
    Exploring the Value of Urine Proteomics-based Dynamic Surveillance for Early Recurrence After Radical Surgery for Hepatocellular Carcinoma: a Prospective Cohort Study
    Phase
    Not given
    Started
    2025-02
    Registry
    NCT06861114

    Age 18 years to 75 years (registered criteria)

    Led by Zhujiang HospitalGuangzhou

  14. Recruiting
    Lenvatinib, Sintilimab, and DEB-TACE With/Without HAIC for HCC >7 cm With PVTT
    Phase
    Phase 2
    Started
    2025-04
    Registry
    NCT06904183

    Age 18 years to 75 years (registered criteria)

    Led by Second Affiliated Hospital of Guangzhou Medical UniversityGuangzhou

  15. Recruiting
    Lenvatinib Plus SIRT vs Lenvatinib in TACE-Refractory HCC
    Phase
    Phase 2
    Started
    2025-04
    Registry
    NCT06904196

    Age 18 years to 75 years (registered criteria)

    Led by Second Affiliated Hospital of Guangzhou Medical UniversityGuangzhou

  16. Recruiting
    Study of ZGGS18 in Combination With ZG005 in Patients With Advanced Solid Tumors
    Phase
    Phase 1/Phase 2
    Started
    2025-05
    Registry
    NCT06938880

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteGuangzhou

  17. Recruiting
    Computer-Aided Diagnosis for Hepatocellular Carcinoma Microvascular Invasion
    Phase
    Not given
    Started
    2025-09
    Registry
    NCT07170345

    Age 18 years to 18 years (registered criteria)

    Lead sponsor is not a listed hospital; 12 listed hospitals as study sitesBeijing, Chengdu, Fuzhou, Guangzhou, Nanning, Shanghai, Shenyang, Wenzhou, Zhengzhou, Zhuhai

  18. Recruiting
    Phase I Clinical Study To Evaluate Pharmacokinetic Profile, Safety, Efficacy and Immunogenicity Of Ipilimumab Biosimilar HLX13 Vs. YERVOY® (US-Sourced YERVOY®) As A First-Line Treatment For Patients With Unresectable Hepatocellular Carcinoma
    Phase
    Phase 1
    Started
    2025-11
    Registry
    NCT07176650

    Age 18 years to 65 years (registered criteria)

    Lead sponsor is not a listed hospital; 27 listed hospitals as study sitesBeijing, Bengbu, Changchun, Chengdu, Fuzhou, Guangzhou, Haikou, Hangzhou, Harbin, Hefei, Nanchang, Nanjing, Nanning, Shanghai, Shenyang, Shijiazhuang, Tianjin, Wuhan, Xi'an, Zhengzhou

  19. Recruiting
    Systemic Chemotherapy With FOLFOX Plus Atezolizumab & Bevacizumab for Patients With Advanced HCC Who Previously Received Atezolizumab & Bevacizumab
    Phase
    Phase 2
    Started
    2025-09
    Registry
    NCT07192185

    Age 18 years to 75 years (registered criteria)

    Led by Sun Yat-sen University Cancer CenterGuangzhou

  20. Recruiting
    Dalpiciclib Plus Camrelizumab for HCC Patients Who Have Previously Received ICI Treatment
    Phase
    Phase 2
    Started
    2025-11
    Registry
    NCT07238881

    Age 18 years to 75 years (registered criteria)

    Led by Sun Yat-sen University Cancer CenterGuangzhou

  21. Recruiting
    A Study of DEG6498 in Participants With Solid Tumors
    Phase
    Phase 1
    Started
    2025-11
    Registry
    NCT07244835

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 3 listed hospitals as study sitesBeijing, Guangzhou

  22. Recruiting
    Camrelizumab and Apatinib With or Without FOLFOX Chemotherapy for Advanced HCC
    Phase
    Phase 3
    Started
    2025-10
    Registry
    NCT07267806

    Age 18 years to Not stated (registered criteria)

    Led by Sun Yat-sen Memorial HospitalGuangzhou

  23. Recruiting
    DEB-TACE vs cTACE in HCC After TIPS
    Phase
    Phase 3
    Started
    2025-12
    Registry
    NCT07322848

    Age 18 years to 75 years (registered criteria)

    Led by First Affiliated Hospital of Sun Yat-sen UniversityGuangzhou

  24. Recruiting
    ABSK-011+BSC vs. Placebo+BSC in Previously Treated Advanced HCC With FGF19 Overexpression
    Phase
    Phase 2
    Started
    2025-06
    Registry
    NCT07327034

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 39 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Ganzhou, Guangzhou, Guilin, Hangzhou, Hefei, Jinan, Nanchang, Nanjing, Nanning, Nantong, Shanghai, Shenyang, Tianjin, Wuhan, Xi'an, Xuzhou, Yinchuan, Zhengzhou

  25. Recruiting
    QL1706 in Combination With Bevacizumab and RALOX HAIC for Hepatocellular Carcinoma With Vp3/4 PVTT
    Phase
    Phase 2
    Started
    2025-12
    Registry
    NCT07327788

    Age 18 years to Not stated (registered criteria)

    Led by Nanfang HospitalGuangzhou

  26. Recruiting
    MDN-001 Injection for the Treatment of Unresectable Primary Hepatocellular Carcinoma.
    Phase
    Phase 1
    Started
    2025-08
    Registry
    NCT07391839

    Age 18 years to 80 years (registered criteria)

    Lead sponsor is not a listed hospital; 8 listed hospitals as study sitesFuzhou, Guangzhou, Hangzhou, Hefei, Jinan, Nanjing, Shanghai, Zhengzhou

  27. Recruiting
    Impact of Emotional Status on Prognosis of Patients With BCLC Stage B/C Hepatocellular Carcinoma Undergoing Hepatic Arterial Infusion Chemotherapy Combined With Targeted and Immunotherapy
    Phase
    Not given
    Started
    2025-12
    Registry
    NCT07436845

    Age 18 years to Not stated (registered criteria)

    Led by Nanfang HospitalGuangzhou

  28. Recruiting
    Anlotinib + Benmelstobart + HAIC in Unresectable HCC: A Phase II Study
    Phase
    Phase 2
    Started
    2025-04
    Registry
    NCT07806292

    Age 18 years to 75 years (registered criteria)

    Led by Sun Yat-sen Memorial HospitalGuangzhou

  29. Recruiting
    Cryoablation Combined With Cardonilizumab and Bevacizumab in Hepatocellular Carcinoma With Pulmonary Metastases
    Phase
    N/A
    Started
    2024-02
    Registry
    NCT06265350

    Age 18 years to 75 years (registered criteria)

    Led by Sun Yat-sen University Cancer CenterGuangzhou

  30. Recruiting
    A Phase I Study to Evaluate the Safety, Pharmacokinetics and Antitumor Activity of HC010 in Patients With Advanced Solid Tumors
    Phase
    Phase 1
    Started
    2024-03
    Registry
    NCT06307925

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteGuangzhou

  31. Recruiting
    Combination of SBRT and Immunotherapy in Small Hepatocellular Carcinoma (HSBRT2402)
    Phase
    Phase 2
    Started
    2024-04
    Registry
    NCT06313190

    Age 18 years to 75 years (registered criteria)

    Led by Sun Yat-sen University Cancer CenterGuangzhou

  32. Recruiting
    Sintilimab Plus Bevacizumab and SIRT for Intermediate-advanced HCC
    Phase
    Phase 2
    Started
    2024-05
    Registry
    NCT06397222

    Age 18 years to 75 years (registered criteria)

    Led by Second Affiliated Hospital of Guangzhou Medical UniversityGuangzhou

  33. Recruiting
    DEB-TACE+RALOX-HAIC vs DEB-TACE for Large HCC
    Phase
    Phase 2
    Started
    2024-05
    Registry
    NCT06397235

    Age 18 years to 75 years (registered criteria)

    Led by Second Affiliated Hospital of Guangzhou Medical UniversityGuangzhou

  34. Recruiting
    A Phase 1/2 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid Tumors
    Phase
    Phase 1/Phase 2
    Started
    2024-07
    Registry
    NCT06427941

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 16 listed hospitals as study sitesChangsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Nanchang, Nanning, Shijiazhuang, Wenzhou, Wuhan, Xuzhou

  35. Recruiting
    Fruquintinib After ICIs Treatment in Unresectable Hepatocellular Carcinoma
    Phase
    Phase 2
    Started
    2024-12
    Registry
    NCT06446154

    Age 18 years to Not stated (registered criteria)

    Led by Sun Yat-sen University Cancer CenterGuangzhou

  36. Recruiting
    Neoadjuvant HAIC and PD-1 Plus Adjuvant PD-1 for High-risk Recurrent HCC
    Phase
    Phase 2
    Started
    2024-09
    Registry
    NCT06467799

    Age 18 years to 75 years (registered criteria)

    Led by Sun Yat-sen University Cancer CenterGuangzhou

  37. Recruiting
    Checkpoint Inhibitor Combinations Therapy as First Line for HCC Via IT
    Phase
    Phase 2
    Started
    2024-06
    Registry
    NCT06482801

    Age 18 years to 75 years (registered criteria)

    Led by Second Affiliated Hospital of Guangzhou Medical UniversityGuangzhou

  38. Recruiting
    Lenvatinib Plus DEB-TACE and HAIC vs. Lenvatinib Plus DEB-TACE for Large HCC With PVTT
    Phase
    Phase 3
    Started
    2024-08
    Registry
    NCT06492395

    Age 18 years to 75 years (registered criteria)

    Led by Second Affiliated Hospital of Guangzhou Medical UniversityGuangzhou

  39. Recruiting
    Neoadjuvant Intra-tumor Double Immunotherapy for Hepatocellular Carcinoma.
    Phase
    Phase 2
    Started
    2024-07
    Registry
    NCT06492408

    Age 18 years to 75 years (registered criteria)

    Led by Second Affiliated Hospital of Guangzhou Medical UniversityGuangzhou

  40. Recruiting
    Postoperative Adjuvant Therapy of Donafenib for Hepatocellular Carcinoma
    Phase
    N/A
    Started
    2024-08
    Registry
    NCT06581315

    Age 18 years to 75 years (registered criteria)

    Led by Sun Yat-sen Memorial HospitalGuangzhou

  41. Recruiting
    mFOLFOX7 Plus Camrelizumab and Apatinib in BCLC Stage A/B Hepatocellular Carcinoma Patients Beyond Milan Criteria
    Phase
    Phase 2
    Started
    2024-02
    Registry
    NCT06607107

    Age 18 years to 75 years (registered criteria)

    Led by Sun Yat-sen Memorial HospitalGuangzhou

  42. Recruiting
    Correlation Study of Lipid Metabolites as Markers of Hepatocellular Carcinoma
    Phase
    Not given
    Started
    2024-07
    Registry
    NCT06623474

    Age 18 years to 80 years (registered criteria)

    Led by Nanfang HospitalGuangzhou

  43. Recruiting
    Single-arm Clinical Trial of TACE in Combination With Icaritin as Adjuvant Therapy After Surgery in Patients With Hepatocellular Carcinoma at High Risk of Recurrence
    Phase
    Phase 2/Phase 3
    Started
    2024-11
    Registry
    NCT06644937

    Age 18 years to 75 years (registered criteria)

    Led by Zhujiang HospitalGuangzhou

  44. Recruiting
    Y-90 SIRT for Unresectable HCC Larger Than 7cm
    Phase
    Phase 2
    Started
    2024-12
    Registry
    NCT06707233

    Age 18 years to 75 years (registered criteria)

    Led by Second Affiliated Hospital of Guangzhou Medical UniversityGuangzhou

  45. Recruiting
    Plasma Sphingolipid Metabolites and Radiotherapy Efficacy in Hepatocellular Carcinoma
    Phase
    Not given
    Started
    2024-09
    Registry
    NCT06864221

    Age 18 years to 80 years (registered criteria)

    Led by Nanfang HospitalGuangzhou

  46. Recruiting
    Downstaging Protocol Containing Immunotherapy for HCC Beyond the Milan Criteria Before Liver Transplantation
    Phase
    Phase 2
    Started
    2023-06
    Registry
    NCT05475613

    Age 18 years to 75 years (registered criteria)

    Led by Sun Yat-sen Memorial HospitalGuangzhou

  47. Recruiting
    Atezolizumab and Bevacizumab Plus TACE-HAIC for Unresectable Advanced HCC: a Phase 2 Clinical Trial
    Phase
    Phase 2
    Started
    2023-03
    Registry
    NCT05751343

    Age 18 years to 75 years (registered criteria)

    Led by Sun Yat-sen University Cancer CenterGuangzhou

  48. Recruiting
    Anlotinib Hydrochloride Capsules Combined With Penpulimab Injection for the Treatment of Hepatocellular Carcinoma at High Risk of Recurrence.
    Phase
    Phase 3
    Started
    2023-05
    Registry
    NCT05862337

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 43 listed hospitals as study sitesBeijing, Bengbu, Changchun, Changsha, Changzhou, Chengdu, Chongqing, Fuzhou, Guangzhou, Haikou, Hangzhou, Hefei, Jinan, Lanzhou, Luzhou, Nanchang, Nanchong, Nanning, Nantong, Ningbo, Shanghai, Shenyang, Taizhou, Tianjin, Urumqi, Wenzhou, Xi'an, Zhengzhou

  49. Recruiting
    Lenvatinib, Tislelizumab Combined With RALOX Regimen HAIC in Advanced Hepatocellular Carcinoma
    Phase
    Phase 2
    Started
    2023-09
    Registry
    NCT05954897

    Age 18 years to Not stated (registered criteria)

    Led by Guangdong Provincial People's HospitalGuangzhou

  50. Recruiting
    TACE Plus Atezolizumab/Bevacizumab and I-125 Seeds Brachytherapy for HCC With Branch PVTT
    Phase
    N/A
    Started
    2023-08
    Registry
    NCT05984511

    Age 18 years to 75 years (registered criteria)

    Led by Third Affiliated Hospital of Sun Yat-sen UniversityGuangzhou

  51. Recruiting
    Sintilimab+Bevacizumab+TACE vs. Lenvatinib+TACE for Advanced HCC
    Phase
    Phase 3
    Started
    2023-08
    Registry
    NCT05985798

    Age 18 years to Not stated (registered criteria)

    Led by Second Affiliated Hospital of Guangzhou Medical UniversityGuangzhou

  52. Recruiting
    SIRT for Potentially Resectable HCC
    Phase
    N/A
    Started
    2023-08
    Registry
    NCT05994859

    Age 18 years to 75 years (registered criteria)

    Led by Second Affiliated Hospital of Guangzhou Medical UniversityGuangzhou

  53. Recruiting
    Perioperative Sintilimab Plus Bevacizumab Biosimilar and TACE-HAIC for HCC Patients With PVTT: A Phase-2 Clinical Trial
    Phase
    Phase 2
    Started
    2023-09
    Registry
    NCT06031285

    Age 18 years to 75 years (registered criteria)

    Led by Sun Yat-sen University Cancer CenterGuangzhou

  54. Recruiting
    Concurrently vs Sequentially Combined HAIC With Targeted and Immunotherapy in Potentially Resectable HCC
    Phase
    Phase 3
    Started
    2023-10
    Registry
    NCT06041477

    Age 18 years to 75 years (registered criteria)

    Led by Sun Yat-sen University Cancer CenterGuangzhou

  55. Recruiting
    Prediction of Hepatocellular Carcinoma Recurrence After Curative Treatment by Longitudinal Monitoring MRD Based on ctDNA
    Phase
    Not given
    Started
    2023-11
    Registry
    NCT06157060

    Age 18 years to 75 years (registered criteria)

    Led by Zhujiang Hospital; 3 listed hospitals as study sitesGuangzhou

  56. Recruiting
    Infusional FOLFOX Plus Camrelizumab and Apatinib vs HAIC-FOLFOX Plus Camrelizumab and Apatinib for Advanced HCC
    Phase
    Phase 3
    Started
    2023-07
    Registry
    NCT06172205

    Age 18 years to 75 years (registered criteria)

    Led by Sun Yat-sen Memorial HospitalGuangzhou

  57. Recruiting
    FOLFOX-HAIC Plus Lenvatinib and Toripalimab vs. FOLFOX-HAIC Plus Lenvatinib for Advanced Hepatocellular Carcinoma: a Randomized Controlled and Double-blind Trial
    Phase
    Phase 3
    Started
    2023-12
    Registry
    NCT06201065

    Age 18 years to 75 years (registered criteria)

    Led by Sun Yat-sen University Cancer CenterGuangzhou

  58. Recruiting
    CT011 Autologous CAR-T Cells in Patients With Hepatocellular Carcinoma at Risk of Recurrence After Surgical Resection
    Phase
    Phase 1
    Started
    2023-10
    Registry
    NCT06560827

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 14 listed hospitals as study sitesBeijing, Changsha, Chengdu, Fuzhou, Guangzhou, Hangzhou, Shanghai, Shenyang, Tianjin, Wuhan, Zhengzhou

  59. Recruiting
    Study on the Treatment of Hepatitis B Virus(HBV) Infected Individuals With Peginterferon α-2b Combined With NA.
    Phase
    Not given
    Started
    2023-05
    Registry
    NCT06746701

    Age 18 years to 65 years (registered criteria)

    Led by Xiangya Hospital; 1 listed hospital as study siteChangsha, Guangzhou

  60. Recruiting
    Prospective Collection of Therapeutic Efficacy and Safety Data in Patients with Unresectable Hepatocellular Carcinoma
    Phase
    Not given
    Started
    2023-03
    Registry
    NCT06788353

    Age 18 years to 75 years (registered criteria)

    Led by First Affiliated Hospital of Sun Yat-sen UniversityGuangzhou

  61. Recruiting
    Efficacy and Safety of ALSS Treatment for ICIs-LF in Patients With HCC
    Phase
    N/A
    Started
    2022-08
    Registry
    NCT05484908

    Age 18 years to 65 years (registered criteria)

    Led by Third Affiliated Hospital of Sun Yat-sen UniversityGuangzhou

  62. Recruiting
    Lenvatinib Plus I-125 Seed Brachytherapy vs. Lenvatinib for TACE-refractory HCC
    Phase
    Phase 3
    Started
    2022-11
    Registry
    NCT05608213

    Age 18 years to 75 years (registered criteria)

    Led by Second Affiliated Hospital of Guangzhou Medical UniversityGuangzhou

  63. Recruiting
    Neo-TACE-HAIC for High-risk BCLC A Stage HCC (NeoconceptA)
    Phase
    N/A
    Started
    2021-02
    Registry
    NCT04777942

    Age 18 years to 75 years (registered criteria)

    Led by Sun Yat-sen University Cancer CenterGuangzhou

  64. Recruiting
    Trametinib Combined With Everolimus and Lenvatinib for Recurrent/Refractory Advanced Solid Tumors
    Phase
    Phase 2
    Started
    2021-01
    Registry
    NCT04803318

    Age 18 years to 85 years (registered criteria)

    Led by Second Affiliated Hospital of Guangzhou Medical UniversityGuangzhou

  65. Recruiting
    Intratumor CpG-ODN Injection Boosters Immune Killing Against in Situ Tumor Antigen Release for Advanced Solid Tumors
    Phase
    Phase 1
    Started
    2021-03
    Registry
    NCT04952272

    Age 18 years to 80 years (registered criteria)

    Led by Second Affiliated Hospital of Guangzhou Medical UniversityGuangzhou

  66. Recruiting
    Phase Ib/II Trial of Envafolimab Plus Lenvatinib for Subjects With Solid Tumors
    Phase
    Phase 1/Phase 2
    Started
    2021-11
    Registry
    NCT05024214

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 16 listed hospitals as study sitesBeijing, Bengbu, Changchun, Dalian, Fuzhou, Guangzhou, Hangzhou, Harbin, Shanghai, Shenyang, Tianjin, Zhengzhou, Zhuhai

  67. Recruiting
    Tislelizumab or Tislelizumab Combined With Lenvatinib Neo-adjuvant Treatment for Resectable RHCC
    Phase
    Phase 2
    Started
    2020-12
    Registry
    NCT04615143

    Age 18 years to 75 years (registered criteria)

    Led by First Affiliated Hospital of Sun Yat-sen UniversityGuangzhou

  68. Recruiting
    Intra-tumor Injection of Drug-eluting Microspheres With Multiple Drugs
    Phase
    Phase 2
    Started
    2020-11
    Registry
    NCT04770207

    Age 18 years to 99 years (registered criteria)

    Led by Second Affiliated Hospital of Guangzhou Medical UniversityGuangzhou

  69. Recruiting
    Infusion of PD1/PDL1/CTLA4 Inhibitors Via Hepatic Arterial for Immunotherapy of Hepatocellular Carcinoma
    Phase
    Phase 3
    Started
    2019-01
    Registry
    NCT03949231

    Age 18 years to 80 years (registered criteria)

    Led by Second Affiliated Hospital of Guangzhou Medical UniversityGuangzhou

  70. Recruiting
    Trans-Artery/Intra-Tumor Infusion of Checkpoint Inhibitors Plus Chemodrug for Immunotherapy of Advanced Solid Tumors
    Phase
    Phase 2/Phase 3
    Started
    2018-11
    Registry
    NCT03755739

    Age 18 years to Not stated (registered criteria)

    Led by Second Affiliated Hospital of Guangzhou Medical UniversityGuangzhou

  71. Recruiting
    GPC3-CAR-T Cells for Immunotherapy of Cancer With GPC3 Expression
    Phase
    Phase 1
    Started
    2017-07
    Registry
    NCT03198546

    Age 18 years to 75 years (registered criteria)

    Led by Second Affiliated Hospital of Guangzhou Medical University; 1 listed hospital as study siteGuangzhou

  72. Not yet recruiting
    Benmelstobart Plus Anlotinib Combined With SBRT for Patients With Hepatocellular Carcinoma Failing First-Line Targeted Therapy
    Phase
    Phase 2
    Started
    2026-04
    Registry
    NCT07537777

    Age 18 years to Not stated (registered criteria)

    Led by Nanfang HospitalGuangzhou

  73. Not yet recruiting
    Nanocrystalline Megestrol Acetate Versus Placebo for Anorexia in Patients With Unresectable Hepatocellular Carcinoma Receiving TACE Combined With Targeted and Immunotherapy
    Phase
    Phase 2
    Started
    2026-06
    Registry
    NCT07565415

    Age 18 years to Not stated (registered criteria)

    Led by Nanfang HospitalGuangzhou

  74. Not yet recruiting
    Yttrium-90 Carbon Microsphere Radioembolization in Previously Treated Hepatocellular Carcinoma
    Phase
    Phase 2
    Started
    2026-06
    Registry
    NCT07657273

    Age 18 years to Not stated (registered criteria)

    Led by Second Affiliated Hospital of Guangzhou Medical UniversityGuangzhou

  75. Not yet recruiting
    The Efficacy and Safety of Donafenib Plus PD-1/L1 Monoclonal Antibodies Plus TACE or HAIC as First-line Treatment for Unresectable Hepatocellular Carcinoma A Multi-center, Retrospective Clinical Study
    Phase
    Not given
    Started
    2026-07
    Registry
    NCT07724951

    Age 18 years to Not stated (registered criteria)

    Led by Zhongshan Hospital, Fudan University; 6 listed hospitals as study sitesGuangzhou, Harbin, Nanning, Qingdao, Shanghai

  76. Not yet recruiting
    Surgery vs. Watch-and-Wait Strategy in Complete Responders for Hepatocellular Carcinoma
    Phase
    N/A
    Started
    2026-12
    Registry
    NCT07866612

    Age 18 years to 80 years (registered criteria)

    Led by West China Hospital; 8 listed hospitals as study sitesBeijing, Chengdu, Chongqing, Fuzhou, Guangzhou, Nanjing, Shanghai

  77. Not yet recruiting
    Lenvatinib Plus Bevacizumab and PD-1 Inhibition Versus Bevacizumab Plus PD-1 Inhibition After Progression on Bevacizumab Plus Sintilimab in Unresectable Hepatocellular Carcinoma: A Prospective, Randomized, Two-Cohort, Phase II Study
    Phase
    Phase 2
    Started
    2026-10
    Registry
    NCT07870772

    Age 18 years to 80 years (registered criteria)

    Led by Sun Yat-sen University Cancer CenterGuangzhou

  78. Not yet recruiting
    Multimodal Liquid-Biopsy Omics Biomarkers of Treatment Response in Breast Cancer
    Phase
    Not given
    Started
    2026-10
    Registry
    NCT07880106

    Age 18 years to 80 years (registered criteria)

    Led by Sun Yat-sen Memorial HospitalGuangzhou

  79. Not yet recruiting
    FOLFOX Plus Lenvatinib Adjuvant Therapy for Hepatocellular Carcinoma Post-Liver Transplantation
    Phase
    Phase 1/Phase 2
    Started
    2025-01
    Registry
    NCT06409637

    Age 18 years to 75 years (registered criteria)

    Led by Sun Yat-sen Memorial HospitalGuangzhou

  80. Not yet recruiting
    Liver Cancer Prognosis Investigation Study
    Phase
    Not given
    Started
    2025-04
    Registry
    NCT06623734

    Age 18 years to 80 years (registered criteria)

    Led by Sun Yat-sen University Cancer CenterGuangzhou

  81. Not yet recruiting
    SBRT Combined with Camrelizumab and Apatinib for Conversion Therapy in Patients with Unresectable Hepatocellular Carcinoma.
    Phase
    Phase 2/Phase 3
    Started
    2025-01
    Registry
    NCT06739317

    Age 18 years to Not stated (registered criteria)

    Led by First Affiliated Hospital of Sun Yat-sen UniversityGuangzhou

  82. Not yet recruiting
    Effect of Prehabilitation During the Conversion Therapy on Postoperative Outcomes in Unresectable Hepatocellular Carcinoma
    Phase
    N/A
    Started
    2025-01
    Registry
    NCT06749678

    Age 18 years to 75 years (registered criteria)

    Led by Sun Yat-sen Memorial HospitalGuangzhou

  83. Not yet recruiting
    A Clinical Trial Assessing the Safety and Efficacy of Biodegradable Magnesium Embolic Microspheres for Primary Hepatocellular Carcinoma
    Phase
    Phase 3
    Started
    2025-01
    Registry
    NCT06779461

    Age 18 years to 80 years (registered criteria)

    Lead sponsor is not a listed hospital; 7 listed hospitals as study sitesBengbu, Guangzhou, Lanzhou, Nanjing, Shanghai, Tianjin, Zhengzhou

  84. Not yet recruiting
    Icariin Soft Capsules Combined With TACE as Adjuvant Therapy for HCC
    Phase
    Phase 2
    Started
    2025-03
    Registry
    NCT06900478

    Age 18 years to 80 years (registered criteria)

    Led by Third Affiliated Hospital of Sun Yat-sen UniversityGuangzhou

  85. Not yet recruiting
    29-Gene Liver Cancer Subtype and Immunotherapy Effectiveness
    Phase
    Not given
    Started
    2025-08
    Registry
    NCT07100236

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 12 listed hospitals as study sitesBeijing, Fuzhou, Guangzhou, Hangzhou, Hefei, Shanghai, Wenzhou, Zhengzhou

  86. Not yet recruiting
    Value of Dynamic Monitoring of Early Recurrence of Hepatocellular Carcinoma After Radical Resection Based on CTCS
    Phase
    Not given
    Started
    2024-04
    Registry
    NCT06317896

    Age 18 years to 75 years (registered criteria)

    Led by Zhujiang Hospital; 1 listed hospital as study siteGuangzhou

  87. Not yet recruiting
    Compare the Accuracy of ctDNA-MRD and MVI Result in Predicting Postoperative Recurrence of Hepatocellular Carcinoma
    Phase
    Not given
    Started
    2024-06
    Registry
    NCT06449846

    Age 18 years to 75 years (registered criteria)

    Led by Zhujiang Hospital; 1 listed hospital as study siteGuangzhou

  88. Not yet recruiting
    SBRT Plus Lenvatinib and TACE for Advanced Primary HCC: A Phase 3 Trial (SEARCH)
    Phase
    Phase 3
    Started
    2023-03
    Registry
    NCT05718232

    Age 18 years to 75 years (registered criteria)

    Led by First Affiliated Hospital of Sun Yat-sen UniversityGuangzhou

  89. Enrolling by invitation
    A Multicenter Prospective Observational Study of Computer-aided Risk Perception and Prognosis Prediction in the Whole Process of Laparoscopic Hepatobiliary and Pancreatic Surgery
    Phase
    Not given
    Started
    2024-09
    Registry
    NCT06647264

    Age 18 years to 80 years (registered criteria)

    Led by Nanfang HospitalGuangzhou

  90. Enrolling by invitation
    Observational Study for SIR-Spheres Therapy for the Treatment of HCC Patients in China
    Phase
    Not given
    Started
    2024-08
    Registry
    NCT06712017

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 4 listed hospitals as study sitesBeijing, Guangzhou, Shanghai

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

Disease research in Guangzhou

Each number is papers led on that disease, 2021–2025. “Open” counts open trials the hospital leads. Hospitals A–Z; this is not a ranking.

A blank cell means no papers or trials were found in these records. It does not mean the hospital does not treat that disease.

Papers led and open trials led by hospitals in Guangzhou, by disease
CancerBlood disordersOther diseases
HospitalNasopharyngeal carcinomaOesophageal squamous cell carcinomaHepatocellular carcinomaStomach cancerHepatoblastomaRetinoblastomaChordomaOsteosarcomaGastrointestinal stromal tumourNeuroblastomaEwing sarcomaMultiple myelomaB-cell acute lymphoblastic leukaemiaAplastic anaemiaHaemophagocytic lymphohistiocytosisBeta thalassaemiaHaemophilia AAtypical haemolytic uraemic syndromeThrombotic thrombocytopenic purpuraFanconi anaemiaNeuromyelitis optica spectrum disorderIgG4-related diseaseMyasthenia gravisMoyamoya diseaseWilson diseaseBiliary atresiaAnti-NMDA receptor encephalitisTakayasu arteritisHepatic echinococcosisIdiopathic pulmonary fibrosisLymphangioleiomyomatosisAmyotrophic lateral sclerosisSpinal muscular atrophyFabry diseasePompe diseaseDuchenne muscular dystrophyBehçet diseaseAlport syndromeIgA nephropathyGaucher diseaseNiemann–Pick disease type COsteogenesis imperfectaPrimary biliary cholangitisPrimary sclerosing cholangitisCongenital diaphragmatic herniaHirschsprung diseaseInherited epidermolysis bullosaHereditary angioedemaFamilial adenomatous polyposisLeber hereditary optic neuropathyMajeed syndromeNGLY1 deficiencyISG15 deficiencyShortlist
Affiliated Brain Hospital of Guangzhou Medical University广州医科大学附属脑科医院nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone1nonenonenonenone2nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
Affiliated Cancer Hospital of Guangzhou Medical University广州医科大学附属肿瘤医院291 open13118nonenonenone0none102nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone2nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
Affiliated Hexian Memorial Hospital of Southern Medical University广州市番禺区妇幼保健院nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone1nonenonenonenonenonenonenonenone
Affiliated Hospital of Southern China University of Technology华南理工大学医院nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone0nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
Affiliated Hospital, Sun Yat-sen University中山大学附属口腔医院nonenonenonenonenonenonenone0nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
Affiliated Tumor Hospital of Guangzhou Medical University广州医科大学附属肿瘤医院nonenonenone0nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
Air Force Hospital中国人民解放军南部战区空军医院nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone0nonenonenonenonenonenonenonenonenonenonenonenonenonenone
Children Hospital广东省妇幼保健院nonenonenonenonenonenonenonenonenone0nonenonenonenonenone6nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone01nonenonenonenonenonenonenone
Children's Hospital, Guangzhou Medical University广州医科大学附属妇女儿童医疗中心nonenonenonenonenonenonenonenonenonenonenonenonenonenonenone1nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
Children's Medical Center广州医科大学附属妇女儿童医疗中心nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone1nonenonenonenonenonenonenone
Dermatology Hospital上海市皮肤病医院nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone1nonenone1nonenonenonenonenonenone
Dermatology Hospital, Southern Medical University南方医科大学皮肤病医院、广东省皮肤病医院nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone0nonenonenonenonenonenone
Eighth People's Hospital of Guangzhou Affiliated to Guangzhou Medical College广州医科大学附属市八医院nonenonenonenonenonenonenonenonenone0nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
Fifth Affiliated Hospital of Guangzhou Medical University广州医科大学附属第五医院15nonenonenonenonenonenonenone0nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone0nonenonenonenonenonenonenonenonenonenone
Fifth Affiliated Hospital of Southern Medical University南方医科大学第五附属医院nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone1nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
First Affiliated Hospital of Guangdong Pharmaceutical University广东药科大学附属第一医院4nonenonenonenonenonenone0none1nonenonenonenonenonenonenonenonenonenonenonenonenonenone3nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
First Affiliated Hospital of Guangzhou Medical University广州医科大学附属第一医院63nonenonenonenonenone0none1nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone00none213nonenonenonenonenonenonenonenonenonenonenone1nonenonenonenonenone0nonenonenonenone
First Affiliated Hospital of Guangzhou University广州中医药大学第一附属医院nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone0nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
First Affiliated Hospital of Guangzhou University of Chinese Medicine广州中医药大学第一附属医院2none3212nonenonenone2nonenonenone2nonenonenone00nonenonenonenonenone6nonenonenonenone1none3nonenonenonenonenonenonenonenone0nonenonenonenonenonenonenonenonenonenonenonenonenonenone
First Affiliated Hospital of Jinan University暨南大学附属第一医院165451 open21none0none912none5nonenonenone2nonenonenonenonenonenone4none2none0nonenone1nonenonenonenonenonenonenone10nonenonenonenonenonenone22nonenonenonenonenonenone
First Affiliated Hospital of Sun Yat-sen University中山大学附属第一医院143 open201 open2196 open525103392 open01181none25nonenonenonenone2none2846122019none2400540222 open0nonenone10none1none00nonenonenonenone
First Affiliated Hospital of Sun Yet-sen University中山大学附属第一医院nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone0nonenonenonenonenonenonenonenonenonenonenonenonenonenone
First Affiliated Hospital, University of Chinese Medicine广州中医药大学第一附属医院nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone1nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
Fuda Cancer Hospital广州复大肿瘤医院0none00nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
Guangdong Clifford Hospital广东祈福医院nonenonenonenonenonenonenone1nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
Guangdong Hospital广东省中医院nonenonenonenonenonenonenonenone1nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone0nonenonenonenonenonenonenonenonenonenonenonenonenonenone
Guangdong Hospital, Guangzhou University of Chinese Medicine广东省中医院nonenonenonenonenonenonenone0nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
Guangdong Province Hospital广东省人民医院nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone1nonenonenonenonenonenonenonenone0nonenonenonenonenonenonenonenonenonenonenonenonenonenone
Guangdong Province Traditional Chinese Medical Hospital广东省中医院nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone0nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
Guangdong Provincial Hospital of Chinese Medicine广东省中医院4none2512nonenonenone2031nonenonenonenone0nonenonenonenone4nonenonenonenonenone0nonenone214nonenonenonenonenonenone6nonenonenone2nonenonenonenonenonenonenonenonenonenone
Guangdong Provincial People's Hospital广东省人民医院1419541 open211 open1211110none31nonenone1nonenonenonenone331nonenonenonenone0none2none1none1nonenone1none81 opennonenonenone41nonenonenonenonenonenonenonenonenone
Guangdong Provincial Second Hospital广东省第二人民医院nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone1nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
Guangdong Second Provincial General Hospital广东省第二人民医院3none16nonenonenonenone2none1none31 opennonenone2nonenonenonenonenonenonenonenonenonenonenone4nonenone1none1nonenonenone10nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
Guangdong Women and Children's Hospital广东省妇幼保健院nonenonenonenonenonenonenone1nonenone1nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
Guangzhou Chest Hospital广州市胸科医院nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone0nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
Guangzhou Dongsheng Hospital广州市东升医院(广州市老年病康复医院)nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone0nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
Guangzhou Eighth People's Hospital广州市第八人民医院(嘉禾院区)nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone0nonenonenonenonenonenonenonenonenone
Guangzhou First People's Hospital广州市第一人民医院2nonenone8nonenonenone301none0none13none1nonenone11nonenonenonenonenonenone41none2nonenonenonenonenone2nonenone10nonenone0nonenonenonenonenonenonenonenonenonenone
Guangzhou General Hospital中国人民解放军南部战区总医院nonenonenonenonenonenonenone0none00nonenone0nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
Guangzhou Hospital广州市中西医结合医院nonenonenonenone0nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
Guangzhou Orthopedics Hospital广州市正骨医院nonenonenonenonenonenonenone0nonenone0nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
Guangzhou Panyu Central Hospital广州医科大学附属番禺中心医院0nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
Guangzhou Red Cross Hospital广州市红十字会医院nonenonenonenonenonenonenone1nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone1nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone0nonenonenonenone
Guangzhou Women and Children's Medical Center广州市妇女儿童医疗中心2nonenonenone93none10321 opennonenone21 opennonenone191 open0nonenonenone1nonenonenone2193nonenone1none0nonenone12none201none1none0117nonenonenonenonenonenonenone
Hexian Memorial Hospital广州市番禺区妇幼保健院nonenonenonenonenonenonenonenone1nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
Huadu Distinct People's Hospital广州市花都区人民医院nonenonenonenonenonenonenone1nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
Huadu District People's Hospital广州市花都区人民医院nonenonenonenonenonenonenonenonenonenonenonenonenonenonenone1nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
Integrated Hospital, Southern Medical University南方医科大学中西医结合医院7nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
Memorial Hospital, Sun Yat-sen University中山大学孙逸仙纪念医院nonenonenonenonenonenonenonenonenonenonenonenonenonenonenone0nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
Nanfang Hospital南方医科大学南方医院336 open84 open1277 open12712 open00none622none38nonenone2191nonenone3none16nonenone7nonenone5none612none0none051 opennonenonenone1none10nonenone2nonenonenonenone
Nangfang Hospital南方医科大学南方医院nonenonenonenonenonenonenonenonenonenonenonenonenonenonenone0nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
Panyu Central Hospital广州医科大学附属番禺中心医院nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone1nonenonenonenonenonenonenonenonenonenonenonenonenonenone
Panyu Hospital广州市番禺区中医院nonenonenonenonenonenonenone0nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
Second Affiliated Hospital of Guangzhou Medical University广州医科大学附属第二医院4none3918 open41 opennonenonenone1none1none50nonenone20nonenonenone2nonenonenonenonenone0nonenone3nonenonenonenonenonenonenonenone0nonenonenonenonenonenonenonenone0nonenonenonenonenone
second affiliated hospital of Sun Yat-sen University中山大学孙逸仙纪念医院nonenonenonenonenonenonenonenonenonenonenonenonenonenonenone0nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
Second Affiliated Hospital of Sun Yat-Sen University中山大学孙逸仙纪念医院nonenonenonenonenonenonenonenonenonenonenonenonenonenonenone0nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
Second Affiliated Hospital, South China University of Technology广州市第一人民医院nonenonenonenonenonenonenone1nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
Second People's Hospital, Southern Medical University广东省第二人民医院nonenonenonenonenonenonenone0nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
Shenzhen Traditional Chinese Medicine Hospital深圳市中医院nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone1nonenonenonenonenonenonenonenonenonenonenonenonenonenone
Sixth Affiliated Hospital of Guangzhou Medical University清远市人民医院nonenonenonenonenonenonenone1nonenonenonenonenonenonenone1nonenone1nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
Sixth Affiliated Hospital of Sun Yat-sen University中山大学附属第六医院none0none455 opennone0none13nonenonenonenonenonenone1nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone1none41nonenonenone1none01none0nonenonenonenone
Southern Hospital南方医科大学南方医院nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone0nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
Southern Medical University Southern Hospital南方医科大学南方医院nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone0nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
Sun Yat-sen Memorial Hospital中山大学孙逸仙纪念医院255 open102 open6610 open115 open2nonenone6081 open214none46nonenonenonenone01 open4nonenonenonenonenonenone1nonenone3nonenonenonenone1none7nonenone000nonenonenonenonenonenonenonenonenone
Sun Yat-sen University Cancer Center中山大学肿瘤防治中心48357 open1378 open28118 open1034 open01 opennone0191 open275 open31 open163none11nonenonenone0nonenonenonenonenonenonenonenonenone2nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
Sun Yet-Sen Memorial Hospital中山大学孙逸仙纪念医院nonenonenonenonenonenonenonenonenone2nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
Third Affiliated Hospital of Guangzhou Medical University广州医科大学附属第三医院4nonenonenonenonenonenone4none0nonenonenonenonenone50nonenonenonenonenonenonenonenonenonenonenonenone1none1nonenonenone1nonenonenonenonenonenonenonenonenonenonenonenone0nonenonenonenone
Third Affiliated Hospital of Guangzhou University of Chinese Medicine广州中医药大学第三附属医院nonenonenonenonenonenonenone0nonenonenonenonenonenonenonenone1nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
Third Affiliated Hospital of Southern Medical University南方医科大学第三附属医院8nonenonenonenonenonenone9nonenone031 opennonenonenonenonenonenonenonenonenonenonenonenonenonenone0nonenonenonenonenonenonenonenonenonenonenone0nonenonenonenonenonenonenonenonenonenonenonenonenonenone
Third Affiliated Hospital of Sun Yat-sen University中山大学附属第三医院10none1713 open151nonenone201none4nonenone10nonenonenone1392 opennone01 open30none222none1none2nonenonenonenone010none0none21nonenonenone0nonenonenonenonenone
Zhongshan Ophthalmic Center中山大学中山眼科中心nonenonenonenonenone251 opennonenonenone0nonenonenonenonenonenonenonenonenonenone4nonenonenonenonenonenonenonenonenonenonenonenonenonenonenone7nonenonenonenonenonenonenonenonenonenonenonenone3nonenonenone
Zhujiang Hospital南方医科大学珠江医院114545 open10none119none6none23 open12 opennonenone1nonenonenonenonenonenonenonenonenonenonenonenonenonenonenone1nonenonenonenonenonenone2nonenonenonenonenonenone5nonenonenonenonenonenonenone

Column labels are short names. Choose one to open that disease in Guangzhou.

Other cities nearby

Straight-line distance from the city centre; counts are hospitals listed for hepatocellular carcinoma.

Counts are listed hospitals only, not every hospital in each city.

Where these numbers come from

Papers

English-language PubMed papers, 2021–2025, where the first or last author lists the hospital first. Definitions

Trials

ClinicalTrials.gov records with the hospital as lead sponsor or site, as of 8 Nov 2026. Search Guangzhou on ClinicalTrials.gov

Locations

Locations are shown at city centres. Check the hospital’s website for its address.

Suggest a correctionDownload the data